Immunotherapy With Autologous Dexosomes for Patients With Stage IV Melanoma

You may be eligible if

• Patients with Stage IV metastatic melanoma with 0-1 prior treatments for metastatic disease.
• All patients must have distant skin, subcutaneous, or nodal metastases (M1a) or lung metastases (M1b), measurable disease, normal lactate dehydrogenase levels, and HLA type A1, A2, or B35.
• Patients must have adequate organ function and an estimated life expectancy of at least 3 months.